RMTG — Regenerative Medical Technology Cashflow Statement
0.000.00%
- $0.45m
- $18.43m
- $5.10m
Annual cashflow statement for Regenerative Medical Technology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.9 | -5.58 | -9.81 | -5.56 | -7.81 |
| Depreciation | |||||
| Non-Cash Items | 1.42 | 1.82 | 5.67 | 2.13 | 0.887 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.55 | 2.49 | 3.42 | 4.06 | 5.94 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -9.88 | -1.11 | -0.419 | 0.851 | -0.707 |
| Capital Expenditures | — | -0.198 | -0.386 | -0.215 | -0.603 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.666 | 0 | — | — | — |
| Sale of Business | |||||
| Cash from Investing Activities | 0.666 | -0.198 | -0.386 | -0.215 | -0.603 |
| Financing Cash Flow Items | — | — | -0.3 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 12.1 | -0.021 | -0.31 | — | 1.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.94 | -1.33 | -1.11 | 0.635 | -0.209 |